About Ribometrix
Ribometrix is a Healthcare company based in Raleigh (United States) founded in 2016. It operates as a RNA-targeted drug discovery platform using three-dimensional structural analysis is provided. Ribometrix has raised $65.3 million across 11 funding rounds from investors including AbbVie, ARE and Vertex Pharmaceuticals. The company has 26 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is RIBOMETRIX, INC. Its competitors include Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Founded in 2016, Ribometrix operates in the biotechnology sector from Raleigh, United States. Three-dimensional structural analysis of RNA is employed to support a drug discovery platform. Novel small molecules are identified through this approach to modulate RNA function and associated proteins in human diseases. The platform focuses on therapeutic development for disease-related targets.
- Headquarters Raleigh, United States
- Employees 26
- SectorsHealthcare
- Email••••••••
- Website ribometrix.com
- Social LinkedIn X
- Legal Name Ribometrix, Inc.
- Total Equity Funding$65.3M (USD)
in 11 rounds
- Latest Funding Round$20M (USD), Series A
Sep 2019
- InvestorsAbbVie
& 14 more
- Employee Count26
Funding Insights of Ribometrix
Ribometrix has successfully raised a total of $65.3M across 11 strategic funding rounds. The most recent funding activity was a Series A round of $20 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.3M
- Total Rounds 11
- Last Round Series A — $20M
- First Round $224,700
(May 2016)
- Investors Count 15
Latest 10 of 11 funding rounds of Ribometrix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $20M | Series A | – | Vertex Pharmaceuticals | – |
| Sep 2019 | $7.8M | Series A | – | SV Health Investors, Illumina Ventures | – |
| Nov 2018 | $30M | Series A | – | M Ventures | |
| Oct 2017 | $7.5M | Seed | – | SV Health Investors, Hatteras Venture Partners | |
| Sep 2017 | $851,166 | Grant | – | – | |
| Apr 2017 | $64,248 | Grant | – | – | |
| Feb 2017 | $345,800 | Grant | – | – | |
| Nov 2016 | $65,000 | Grant | – | – | |
| Sep 2016 | $222,525 | Grant | – | – | |
| Jul 2016 | $75,000 | Debt – Venture | – | – |
15 investors in total: 15 institutional.
Investors in Ribometrix
Ribometrix has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, ARE and Vertex Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on early-stage healthcare startups | – | svhealthinvestors.com | Boston, United States | |
Health tech startups are invested in by Illumina Ventures. | – | illuminaventures.com | Foster City, United States | |
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | – | hatterasvp.com | Durham, United States | |
A venture capital firm focused on life science innovations. | – | mp-healthcare.com | Cambridge, United States | |
Early stage investments focused VC firm | – | acks.com | - | |
Biotech startups are incubated and funded in North Carolina. | 1984 | ncbiotech.org | Durham, United States | |
Venture capital firm investing in multiple sectors | – | m-ventures.com | Amsterdam, Netherlands | |
Venture capital investments are facilitated by Amgen-backed entity. | – | amgenbd.com | Thousand Oaks, United States | |
VC firm focusing on life science sector | – | pappas-capital.com | Durham, United States | |
Developer of drugs for the treatment of multiple disorders | 1989 | vrtx.com | United States |
Investor details for Ribometrix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ribometrix
20 people are tracked at Ribometrix (8 in leadership, 6 in board & advisors, 6 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Katie Warner | VP, RNA Biology | Leadership |
Orshi Kocsis | VP, Human Resources | Leadership |
Jonathan Kearns | Vice President Finance | Leadership |
Murty Changalvala | Associate Director, Medicinal Chemistry | Leadership |
Mattew Friedersdorf | Associate Director, Translational Medicine | Leadership |
Ramamurty Changalvala | Associate Director | Leadership |
Kevin Weeks | Academic Founder | Leadership |
Caleb D. Sutherland | Director, RNA Biology | Leadership |
Mike Dial | Director | Board & advisors |
Mike Clayman | Chairman | Board & advisors |
Hakan Goker | Director | Board & advisors |
Mike Ross | Director | Board & advisors |
John Schneekloth | Scientific Advisor | Board & advisors |
William S. Marshall | Director | Board & advisors |
Brittani Patterson | Scientist II | Team |
Allen Zhang | Senior Accountant | Team |
Raquel Martinez Chacin | Senior Scientist I, Program Leader, And Program Manager, Translational Medicine Team | Team |
Nicholas Taylor | Laboratory Operations Manager | Team |
Laurel Shambley | Contract Manager | Team |
Krista Marran | Scientist II | Team |
Complete people profiles for Ribometrix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ribometrix
3 dated milestones of Ribometrix across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Ribometrix is founded.
- Funding First funding round of $225K.
- Funding Latest funding round, Series A, of $20.0M.
Competitors of Ribometrix
Ribometrix has 9 listed competitors in our database, 9 of them funded. They include Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. |
Detailed competitors of Ribometrix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ribometrix
The website of Ribometrix (ribometrix.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 17% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Ribometrix (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ribometrix
Complete news archive for Ribometrix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ribometrix
Ribometrix was founded in 2016.
Ribometrix is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
Ribometrix is a funded company, having raised a total of $65.3M across 11 funding rounds to date. The company's 1st funding round was a Debt – Venture of $75K, raised on May 2016.
Ribometrix has 26 employees.
Founded in 2016, Ribometrix operates in the biotechnology sector from Raleigh, United States. Three-dimensional structural analysis of RNA is employed to support a drug discovery platform. Novel small molecules are identified through this approach to modulate RNA function and associated proteins in human diseases. The platform focuses on therapeutic development for disease-related targets.
Ribometrix's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Ribometrix has 15 investors. Key investors include AbbVie, ARE, Vertex Pharmaceuticals, HHS, and North Carolina Department of Commerce.
Ribometrix operates through Ribometrix, Inc..